Simplifying Existing Procedure Eases Market Penetration for Photocure
(Thomson Reuters ONE) -
Photocure (PHO.OL) (PHCUF) President and CEO Kjetil Hestdal discusses the
company's photodynamic technology harnessed in Hexvix and Allumera. Hexvix,
branded as Cysview in the U.S., aids in cystoscopy procedures for bladder and
colorectal cancers. Photocure already has a market penetration of 30% in the
Nordic region, says Hestdal, and hopes to replicate that in the 230,000
procedures performed annually in the United States. He discusses the company's
dermatological technology Allumera and details research on Phase II acne
treatment Visonac, which he says has shown good efficacy and comparable results
to existing oral antibiotics, though without some of the negatives.
The conversation includes development expectations for 2013 and 2014 and
partnership details for the company, as well as the company's capital structure.
Click here to watch this exclusive video
About PropThink.com
PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: PropThink via Thomson Reuters ONE
[HUG#1623895]
Unternehmensinformation / Kurzprofil:
Datum: 03.07.2012 - 16:32 Uhr
Sprache: Deutsch
News-ID 162244
Anzahl Zeichen: 1972
contact information:
Town:
New York
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 197 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Simplifying Existing Procedure Eases Market Penetration for Photocure"
steht unter der journalistisch-redaktionellen Verantwortung von
PropThink (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
